Susceptibility to hepatitis B infection, hepatitis B/HIV co-infections and hepatitis B immunity in HIV-positive patients starting HAART in Durban, South Africa

Figures & data

Table 1: Baseline characteristics and CD4 count characteristics of HIV-infected patients (n = 1 066)

Variable	Level	N
Gender, n (%)	Female	530 (49.7%)
	Male	536 (50.3%)
Age group, n (%)	< 12 years	77 (7.2%)
	≥ 12 years	989 (92.8%)
Median CD4 count, cells/mm^3 (IQR)	All patients	167 (60–296)
Median CD4 count, cells/mm^3 (IQR)	< 12 years	670 (447–908)
Median CD4 count, cells/mm^3 (IQR)	≥ 12 years	151 (57–269)
Median CD4 count, cells/mm^3 (IQR)	Male	132 (48–245)
Median CD4 count, cells/mm^3 (IQR)	Female	171 (68–291)

Table 2: HBV susceptibility, hepatitis B immunity and HIV/HBV co-infection by age, gender and CD4 count (n = 922)

Variable	Level	HBVsAg– and HBVsAb− (n = 643) (= 69.8%) n (%)	HBVsAg– and HBVsAb+ (n = 248) (= 25.0%) n (%)	HBVsAg+ and HBVsAb+ (n = 31) (= 3.1%) n (%)	p-value
Gender	Female	330 (51.3%)	119 (48.0%)	14 (45.2%)	0.560*
	Male	313 (48.7%)	129 (52.0%)	17 (54.8%)
Median age, years (IQR)		36 (30–44)	30 (11–42)	34 (30–40)
Age group	< 12 years	5 (0.8%)	70 (28.2%)	1 (3.2%)	< 0.001*
	≥ 12 years	638 (99.2%)	178 (71.8%)	30 (96.8%)
Median CD4 count, cells/mm^3 (IQR)		145 (57–260)	294 (124–586)	123 (35–307)
Median CD4 count, cells/mm^3 (IQR)	< 12 years	322 (300–488)	695 (450–909)	113
	>− 12 years	143 (56–256)	204 (84–331)	111 (35–294)	< 0.001**

*Fisher's exact test was used to compare proportions of gender and age group across different HBVsAg categories

**Kruskal Wallis test was used to compare CD4 count distribution across different HBVsAg categories

Figure 1: Age distribution across HBV groups among patients starting HAART.